HIP
CPXX

Hatteras Investment Partners’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

Hatteras Investment Partners’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-70,720
Closed -$780K – 88
2016
Q1 		$780K Buy
+70,720
New +$232K 2.13% 13

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Hatteras Investment Partners's CPXX Position: Q2 2016 in Review

Hatteras Investment Partners sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q2 2016, closing a stake of 70,720 shares — an estimated $780K sold.

Hatteras Investment Partners first reported a position in CPXX in Q1 2016 and held it in 1 quarter. The position peaked at $780K in Q1 2016. 119 funds tracked by Wall St. Rank hold CPXX as of Q2 2016.

  • Hatteras Investment Partners reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q2 2016 after selling out during the quarter.
  • Hatteras Investment Partners sold 70,720 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q2 2016, an estimated $780K.
  • Hatteras Investment Partners first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q1 2016 and held it in 1 quarter.
  • Hatteras Investment Partners's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $780K in Q1 2016.
  • 119 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q2 2016.

Based on Hatteras Investment Partners's 13F filing for Q2 2016, filed 15 Aug 2016.